Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pediatric Transplantation|September 26, 2015
Clostridium difficile infection in the pediatric transplant patientMaribeth R Nicholson, Christy L Osgood, Sari A Acra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2017
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing RegimenChristy L Osgood, Meredith K Chuk, Marc R Theoret, et al.
Scientific Reports|September 28, 2016
18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing SarcomaChristy L Osgood, Mohammed N Tantawy, Nichole Maloney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerJennifer J Gao, Christy L Osgood, Zhou Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project RenewalSundeep Agrawal, Clara Lee, William F Pierce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast CancerSakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Preeti Narayan, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription FactorChristy L Osgood, Nichole Maloney, Christopher G Kidd, et al.
Pageof 2